Breast最新文献

{"title":"P083: Study of HER2-low expression in triple-negative breast cancer","authors":"T. Tran Trung, A. Duong Thi Ngoc, T. Nguyen Van, T Ta Van","doi":"10.1016/j.breast.2025.103953","DOIUrl":"10.1016/j.breast.2025.103953","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103953"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P076: Evaluation of intrinsic molecular subtyping in breast cancer and comparison with the results of the routine immunohistochemical study: The SUBMARIN Study","authors":"L. Bernet Vegue, S. Peláez, M Berná Rubio","doi":"10.1016/j.breast.2025.103947","DOIUrl":"10.1016/j.breast.2025.103947","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103947"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P086: Higher elastography strain ratio (ESR) predicts less distant recurrence in triple-negative breast cancer (TNBC): Softer tumor environment is deleterious?","authors":"H. Wang, Y. Zhu, K. Shen, S Zhu","doi":"10.1016/j.breast.2025.103956","DOIUrl":"10.1016/j.breast.2025.103956","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103956"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P049: The prognostic role of Ki-67 in relation to Oncotype DX Recurrence Score","authors":"C. Markopoulos, A. Koumarianou, V. Venizelos, R. Iosifidou, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, S. Giassas, I. Foivos, V. Gaki, A. Pazaiti, K. Anastasakou, E. Timotheadou, K. Koutsoukos, T. Kontoulis, E. Kostouros, I. Gkioulbasanis, D. Nasikas, D Matheos","doi":"10.1016/j.breast.2025.103932","DOIUrl":"10.1016/j.breast.2025.103932","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103932"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P111: Cost-effectiveness of a breast cancer screening program in Switzerland","authors":"I Salvi","doi":"10.1016/j.breast.2025.103977","DOIUrl":"10.1016/j.breast.2025.103977","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103977"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Raising awareness of alcohol as a modifiable risk factor for breast cancer: A randomized controlled trial comparing the efficacy of accessing an interactive website with a non-interactive website’ [The Breast (2025) 103868]","authors":"Claudia Sardu , Fabrizio Angius , Paolo Contu , Sofia Cosentino , Monica Deiana , Matteo Fraschini , Clelia Madeddu , Elena Massa , Alessandra Mereu , Luigi Minerba , Carola Politi , Silvia Puxeddu , Francesco Salis , Julia M.A. Sinclair , Roberta Agabio","doi":"10.1016/j.breast.2025.103888","DOIUrl":"10.1016/j.breast.2025.103888","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103888"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy","authors":"Jing Yang ,&nbsp;Meng-Yun Zhou ,&nbsp;Bo Yu ,&nbsp;Qing Lin ,&nbsp;Yuan Yao ,&nbsp;Hua-Ling Wu ,&nbsp;Qi-Wei Zhu ,&nbsp;Ming Ye ,&nbsp;Hua-Ying Xie ,&nbsp;Jian-Wei Wu ,&nbsp;Gang Cai ,&nbsp;Rong Cai ,&nbsp;Wei-Xiang Qi ,&nbsp;Jia-Yi Chen ,&nbsp;Lu Cao","doi":"10.1016/j.breast.2025.103879","DOIUrl":"10.1016/j.breast.2025.103879","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT).</div></div><div><h3>Methods</h3><div>Consecutive operable BC patients receiving postoperative RT and trastuzumab with or without pertuzumab between January 2017 and September 2020 at seven tertiary hospitals in China were retrospectively reviewed. Cardiac examinations included echocardiography, electrocardiogram (ECG), NT-proBNP, and cTnI at baseline before RT and during the follow-up. The cardiac event is any new-onset symptomatic heart disease or abnormality in the cardiac examination after RT.</div></div><div><h3>Results</h3><div>In total, 681 patients were enrolled in the analysis, of whom 567 were treated with trastuzumab-alone and 124 patients received dual anti-HER2 therapy. The median follow-up was 11 months. Multivariate analysis showed that left-sided breast cancer (HR 2.38; 95%CI 1.65–3.44, p &lt; 0.001) and IMN RT (HR 1.47; 95 % CI 1.01–2.15, P-value = 0.047) are independent risk factors for ECG abnormalities. Age &gt;50 years is an independent risk factor for developing LVDD (HR 5.16; 95%CI 1.17–22.73, P-value = 0.030). Dosimetric analysis showed that patients who developed subclinical cardiac events had increased mean heart dose (412.0 ± 249.6 vs. 347.2 ± 242.6 cGy, P-value = 0.010). Among right-sided patients or patients receiving anthracycline-based chemotherapy, the dual-targeted cohort had a higher risk of developing ECG abnormalities compared to the trastuzumab-only cohort.</div></div><div><h3>Conclusion</h3><div>Compared with trastuzumab-only, dual anti-HER2 therapy does not increase early cardiac toxicity in combination with postoperative RT in BC patients. Cardiac radiation exposure remains the primary risk factor for early toxicity.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103879"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer","authors":"Paola Zagami ,&nbsp;Angela Esposito ,&nbsp;Beatrice Taurelli Salimbeni ,&nbsp;Pier Paolo Maria Berton Giachetti ,&nbsp;Roberta Scafetta ,&nbsp;Matteo Lambertini ,&nbsp;Massimo Di Maio ,&nbsp;Giuseppe Curigliano ,&nbsp;Carmen Criscitiello ,&nbsp;Saverio Cinieri","doi":"10.1016/j.breast.2025.103875","DOIUrl":"10.1016/j.breast.2025.103875","url":null,"abstract":"<div><h3>Purpose</h3><div>CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines Agency (AIFA) approved the possibility of switching between CDK4/6i for unacceptable toxicity. This study explores oncologists' experiences and future perspectives on CDK4/6 inhibitor switching following this new approval.</div></div><div><h3>Methods</h3><div>With the support of the Italian Association of Medical Oncology (AIOM), we conducted a survey among 92 oncologists to assess the impact of AIFA's approval on patient management.</div></div><div><h3>Results</h3><div>The survey showed that 48 % of participants were not surprised regarding AIFA's decision, with 76 % of respondents believing that this opportunity would significantly influence their treatment choices, enhancing AEs management for patients. Yet, 49 % of respondents emphasized the need for more real world evidence on CDK4/6i switch safety and efficacy. 96 % of respondents reported discontinuation rates between 0% and 25 % of patients, with constipation and hematological toxicity being the most frequent treatment discontinuation reasons. The oncologists prescribing CDK4/6i switch reported that most of these patients were in first line treatment (85 %) and the most common second CDK4/6i most frequently initiated was palbociclib (69 %), then abemaciclib (17 %) and ribociclib (14 %). Among those who started the second CDK4/6i at full dosage, 66 % of patients didn't require a dose reduction.</div></div><div><h3>Conclusion</h3><div>Our survey highlights the importance of allowing CDK4/6i switching, thus likely prompting oncologists to adapt their treatment choices, leading to better AEs management for improving patients’ outcome.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103875"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis","authors":"Yi-Zi Zheng ,&nbsp;Jia-Qi Ying ,&nbsp;Ting-Ting Wu ,&nbsp;Yong-Hui Su ,&nbsp;Ou-Chen Wang","doi":"10.1016/j.breast.2025.103877","DOIUrl":"10.1016/j.breast.2025.103877","url":null,"abstract":"<div><h3>Background</h3><div>Ongoing discussions persist concerning the precedence of neoadjuvant therapy (NAT) relative to adjuvant therapy (AT) for patients with T1c, node-negative, triple-negative breast cancer (TNBC), and pertinent guidelines for these individuals are absent.</div></div><div><h3>Methods</h3><div>Women diagnosed with T1cN0M0-stage TNBC who received chemotherapy and surgery were selected from the Surveillance, Epidemiology and End Results database (2010–2020). To balance baseline characteristics and mitigate selection bias, propensity score matching (PSM) was used to create the NAT and AT cohorts. Kaplan–Meier (KM) analysis and Cox proportional hazards models were performed to assess the prognostic factors for overall survival (OS) and breast cancer–specific survival (BCSS). Logistic regression models were utilized to identify predictive factors for response to NAT.</div></div><div><h3>Results</h3><div>A total of 1033 patient pairs passed the PSM process, resulting in a well-balanced distribution. The KM analysis demonstrated that patients who received AT and those who underwent NAT had similar OS and BCSS, no matter before or after PSM. The multivariate Cox model showed that not achieving pathological complete response (non-pCR) following NAT, compared to AT, was associated with considerably worse OS (hazard ratio [HR], 2.207; 95 % confident intervaI [CI], 1.431–3.405; <em>p</em> &lt; 0.001) and worse BCSS (HR, 2.184; 95 % CI, 1.348–3.537; <em>p</em> = 0.002). The logistic regression model revealed that being under 50 years old and having grade III or undifferentiated disease were independent predictors of pCR.</div></div><div><h3>Conclusions</h3><div>In patients with T1cN0M0-stage TNBC, both NAT and AT resulted in equivalent OS and BCSS. However, NAT precisely helped select patients with worse prognosis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103877"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P090: Gene Mutation Spectrum in Luminal/HER2-low Early Breast Cancer after Neoadjuvant Chemotherapy: A Prospective, Multicenter Cohort Study","authors":"Y. Yang,&nbsp;J. Chen,&nbsp;Y. Zhu,&nbsp;C. Gong,&nbsp;GMS-TEAM.","doi":"10.1016/j.breast.2025.103959","DOIUrl":"10.1016/j.breast.2025.103959","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103959"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}